NeuroTraX-AI targets the blood-brain barrier, a central hurdle in brain medicine and drug safety, as U.S. regulators ...
A phase 3 trial of Kolon TissueGene’s cell-based gene therapy has missed its co-primary endpoints. With a second late-stage study scheduled to report data in October, the biotech is holding off on ...
UAB startup TIXiMED advances TIX100, a novel oral Type 1 diabetes therapy, into Phase 1b clinical testing. The ...
Researchers have unveiled Cas12a2, a groundbreaking CRISPR technology that targets RNA to selectively destroy cancer and ...
Summary: Researchers developed “Core2Edge,” an advanced ex vivo human tissue model that replicates the invasive spread and ...
ProtaGene is proud to announce that it has received Clinical Laboratory Improvement Amendments (CLIA) accreditation from the College of American Pathologists (CAP) for its Heidelberg site to perform ...
Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor ...
Irvine-based biotech firm GlyTR Therapeutics advances pan-cancer therapy developed at UCI toward human trials through ProBio ...
CARLSBAD, Calif.-- (BUSINESS WIRE)--Jul 30, 2026-- ...
Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs.
A UAB study published in Immunity reveals that T cells help develop diverse anti-carbohydrate antibodies after early microbial exposure, offering new insights into immune defense, autoimmune disease, ...
Study demonstrates a new way to study flu-host interactions in their native context and with structural insight.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results